Why the world should keep the hope for an HIV vaccine

By Ethel Makila, Associate Director, Advocacy Policy and Communications at the International AIDS Vaccine Initiative

In commemoration of the 2018 HIV Vaccine Awareness Day (HVAD2018), the International AIDS Vaccine Initiative (IAVI), Africa free of New HIV infections( AfNHi), and Media for Environment, Science, Health and Agriculture (MESHA) with support from AVAC, hosted a science café with scientists, media, community representatives and HIV vaccine advocates.

Discussions of the15 May 2018 forum which took place in Nairobi, Kenya, highlighted the global and regional progress towards HIV vaccine research and development, as well as advocates and community perspectives on the need for an HIV vaccine in Africa.

After close to three decades of research, scientists are still trying to develop a safe, effective and accessible vaccine against HIV. The journey towards finding the vaccine has been full of challenges and necessitated long-term commitments; global collaborations; and millions of dollars in funding.

During the May 15 forum, journalists were eager for answers as to the exact progress of the HIV vaccine development process and why there are still passionate advocates for a seemingly elusive venture.Why the world should keep the hope for an HIV vaccine

In his presentation, IAVI Africa Regional Director Prof Anatoli Kamali highlighted the persistent challenge of new HIV infections despite the great achievements in the fight against HIV and AIDS through treatment and prevention programs.

The rate of new HIV infections over the last 10 years still remains high. In 2016 alone, there were 1.8 million new infections’ said Kamali. ‘Nearly 70 percent of those new infections occurred in sub-Saharan Africa’, he added.

Prof Kamali emphasized that without a vaccine, the world may actually see increases in infection rates. He cited emerging challenges including a resistance to life-saving HIV drugs, and a surge in the growth of the adolescent population in sub Saharan Africa – the population with the highest rate of new HIV infections globally – as a threat to the progress in tackling the HIV epidemic.

As he made a case for the continued investment of time and resources in research to find an HIV vaccine, Prof Kamali reminded the audience that the biggest impacts in the eradication or control of infectious diseases in the history of public health have been achieved through vaccination.

He also referred to recent modeling analyses conducted for low- and middle-income countries which show that even with a 70 percent efficacious and well-adopted vaccine as part of the global HIV/AIDS response, majority of the annual new HIV infections can be prevented.

PATH Advocacy Manager in Kenya, Pauline Irungu added that beyond saving lives, an effective HIV vaccine could potentially improve the social economic out-look for Africa by removing the burden posed by rising costs of treatment and care of HIV infected populations.

‘Since the 1950’s, Global health R&D investment of US$26milion towards polio vaccine has resulted in treatment cost savings worth US$180 billion,’ argued Irungu, adding that overall, research and development is linked to economic prosperityand improved quality of life.

From the community perspective, Inviolata Mmbwavi, the National Coordinator of International Community of Women Living with HIV – Kenya gave a passionate account of why she has dedicated her life to advocate for HIV prevention strategies, particularly awareness creation and vaccine research and development.

‘As a mother, and as a person who got infected at a tender age, the thought of the rising cases of new HIV infections among young people makes my stomach churn’ said Mmbwavi.

‘I look forward to the day we shall have a safe, effective and accessible HIV vaccine for all. Then I can rest assured that we can end HIV and AIDS for good,’ she concluded.

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas